Wedbush Lowers Vigil Neuroscience (NASDAQ:VIGL) Price Target to $13.00

Vigil Neuroscience (NASDAQ:VIGL) had its price objective decreased by equities research analysts at Wedbush from $24.00 to $13.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock.

VIGL has been the topic of several other reports. JMP Securities reaffirmed a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. HC Wainwright reduced their price target on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday. Guggenheim reaffirmed a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Finally, William Blair assumed coverage on shares of Vigil Neuroscience in a report on Wednesday, December 4th. They set an “outperform” rating on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vigil Neuroscience currently has an average rating of “Buy” and a consensus price target of $16.25.

Vigil Neuroscience Trading Up 0.2 %

Shares of VIGL traded up $0.01 during mid-day trading on Friday, hitting $2.12. The company’s stock had a trading volume of 6,174 shares, compared to its average volume of 467,290. The firm has a market capitalization of $86.46 million, a price-to-earnings ratio of -1.04 and a beta of 1.82. The company’s 50-day moving average is $2.34 and its 200-day moving average is $2.80. Vigil Neuroscience has a 52-week low of $1.49 and a 52-week high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). As a group, sell-side analysts predict that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vigil Neuroscience

Institutional investors and hedge funds have recently modified their holdings of the company. Walleye Capital LLC grew its stake in Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after purchasing an additional 92,217 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Vigil Neuroscience during the 3rd quarter worth approximately $442,000. Point72 Asset Management L.P. boosted its holdings in shares of Vigil Neuroscience by 7.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock valued at $5,440,000 after buying an additional 115,000 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Vigil Neuroscience by 41.9% in the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after buying an additional 66,712 shares during the last quarter. Finally, abrdn plc raised its stake in Vigil Neuroscience by 124.9% during the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock worth $898,000 after acquiring an additional 293,461 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.